49. Systemic lupus erythematosus
827 clinical trials,   638 drugs   (DrugBank: 168 drugs),   108 drug target genes,   191 drug target pathways

Searched query = "Systemic lupus erythematosus", "SLE"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
2 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01085084
(ClinicalTrials.gov)
July 20109/3/2010Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus ArthritisA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Systemic Lupus Erythematosus Patients With Active Lupus ArthritisLupus ArthritisDrug: Laquinimod;Other: PlaceboTeva Pharmaceutical IndustriesNULLCompleted18 Years75 YearsBoth82Phase 2United States;Canada
2NCT01085097
(ClinicalTrials.gov)
July 20104/3/2010Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus NephritisA Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combination With Standard of Care (Mycophenolate Mofetil and Steroids)Lupus NephritisDrug: laquinimod;Drug: Mycophenolate Mofetil;Drug: prednisolone/prednisone;Drug: PlaceboTeva Pharmaceutical IndustriesNULLCompleted18 Years75 YearsBoth47Phase 2United States;Canada;France;Russian Federation;United Kingdom